The observation that JNK1 and JNK2 promote obesity (by inhibiting energy expenditure) and cause insulin resistance in peripheral tissues indicates that drugs that block JNK signaling may be therapeutically beneficial for the treatment of pre-diabetes (Sabio and Davis, 2010). Here, MAPK9 is linked to obesity disorder.